American College of Cardiology (ACC) Features Expert Analysis on the Importance of Addressing Anemia With Blood Volume Analysis in Heart Failure Patients

Cites Evidence from Studies Utilizing Daxor’s BVA-100® Blood Volume Analyzer

NEW YORK, July 13, 2021 (GLOBE NEWSWIRE) -- Daxor Corporation (NYSE MKT: DXR), the global leader in blood volume measurement technology, today announces an expert analysis titled, “Anemia and Heart Failure: Guidance for Clinicians and Trialists'' published July 6, 2021 in the American College of Cardiology (ACC) online clinical topics section: The authors focus on detecting and addressing anemia in heart failure (HF) patients, a common and often unrecognized condition causing increased length of hospitalization and worsening outcomes. The document specifically states, “every attempt should be made to measure and know total blood volume” and cites outcome studies that identify total blood volume via Daxor's unique blood volume analysis technology.

The analysis additionally emphasizes the importance of direct measurement of a patient's red blood cell volume, also citing supporting references of research papers and clinical trials applying blood volume measurements using Daxor’s BVA-100 Blood Volume Analyzer. The authors state that “... connecting the current gaps in awareness of anemia prevalence in heart failure patients, the impact of current anemia diagnostics, and the potential for therapeutics to be more precisely targeted to improve safety and outcomes, it becomes clearer to us that there is some missing link—and it just may be how we think about what anemia represents and the priority we place on its measurement, management, and treatment.”

“Over 6 million Americans suffer from heart failure, one of the most prevalent and deadly diseases leading to nearly 1 million deaths and 1 million hospitalizations annually, and addressing anemia effectively is an important part of the solution,” said Michael Feldschuh, CEO and President of Daxor Corporation. “Our proprietary BVA-100 blood test precisely quantifies the intravascular blood, plasma and red cell volume informing anemia and helps guide appropriate treatment strategies -- resulting in significantly better clinical and economic benefits for patients and hospitals.”

In addition to its current FDA-cleared BVA-100 blood test, Daxor is developing next-generation testing platforms under multiple contract awards with the U.S. Department of Defense and support from the National Institutes of Health, slated for release in 2022.

About Daxor Corporation

Daxor Corporation (NYSE: DXR) is the global leader in blood volume measurement technology focused on blood volume testing innovation (organized as an investment company with fully-owned innovative medical instrumentation and biotechnology operations). We developed and market the BVA-100® (Blood Volume Analyzer), the first diagnostic blood test cleared by the FDA to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms. The BVA technology enhances hospital performance metrics in a broad range of surgical and medical conditions, including heart failure and critical care, by informing treatment strategies, resulting in significantly improved multiple measures of patient outcomes. Daxor's mission is to advance healthcare by enabling optimal fluid management with blood volume analysis. Daxor’s vision is optimal blood volume for all. For more information, please visit our website at

Forward-Looking Statements

Certain statements in this release may include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including without limitation, statements regarding the impact of hiring sales staff and expansion of our distribution channels. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this release, including, without limitation, those risk associated with our post-market clinical data collection activities, benefits of our products to patients, our expectations with respect to product development and commercialization efforts, our ability to increase market and physician acceptance of our products, potentially competitive product offerings, intellectual property protection, FDA regulatory actions, our ability to integrate acquired businesses, our expectations regarding anticipated synergies with and benefits from acquired businesses, and additional other risks and uncertainties described in our filings with the SEC. Forward-looking statements speak only as of the date when made. Daxor does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Investor Relations Contact:
Bret Shapiro
Sr. Managing Partner, CORE IR